Allison Toledo Candelario, MD
Ophthalmology · Arecibo, PRNPI 1871881631
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Novartis accounts for 61.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,514 and has fallen 94.4% since, to $84 in 2025.
Across 27 payments — averaging $88.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Genentech USA, Inc.$317
- Regeneron Healthcare Solutions, Inc.$185
- Mallinckrodt Hospital Products Inc.$135
- Regeneron$135
- Alcon$52
- plus $105 from 5 others
Across 20 payments — averaging $7270.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$145K
What the payments were for
- Travel & lodging$1,29154%
- Food & beverage$99642%
- Education$934%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $1,451 |
| Genentech USA, Inc. | 7 | $317 |
| Regeneron Healthcare Solutions, Inc. | 4 | $185 |
| Mallinckrodt Hospital Products Inc. | 2 | $135 |
| Regeneron | 1 | $135 |
| Alcon | 1 | $52 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| AbbVie | 1 | $21 |
| Eyepoint US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,380 in reported general payments places this provider in the 80th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorometholone | 609 | $42,332 |
| LumiganBimatoprost | 111 | $30,140 |
| Prednisolone Acetate | 384 | $15,216 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 379 | $12,553 |
| CombiganBrimonidine Tartrate/Timolol | 55 | $11,810 |
| Latanoprost | 963 | $11,561 |
| RestasisCyclosporine | 14 | $11,212 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $8,136 |
| Brimonidine Tartrate | 434 | $8,111 |
| Ketorolac Tromethamine | 195 | $3,798 |
| Alphagan PBrimonidine Tartrate | 17 | $3,312 |
| Dorzolamide Hcl | 114 | $3,216 |
| Travoprost | 15 | $2,815 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $2,716 |
| Atropine Sulfate | 59 | $2,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $21 | $56,474197 claims |
| AlconSimbrinza | $52 | $2,71613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in Arecibo
- Pedro DavilaArecibo$4K
- Lorena Montalvo-ToledoArecibo$3K
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Armando OliverRio Piedras$251K
- Andres Emanuelli AnzalottaCorozal$50K
- Cristobal Cruz-ColonPonce$44K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.